CTIS2023-507295-40-00进行中（未招募）1 期
Biomarker-Guided Early Clarithromycin Treatment To Prevent Sepsis Progression In Community-Acquired Pneumonia: The REACT Randomized Clinical Trial - REACT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age equal to or above 18 years, Male or female gender, In case of women of reproductive age, willingness to use dual contraceptive method during the study period, Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation, Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain, Community-acquired pneumonia (CAP), PCT =0.25 ng/ml, suPAR =6 ng/ml
排除标准
- •Age below 18 years, Known infection by the human immunodeficiency virus, Any chronic anti-cytokine treatment for more than two months, QTc interval at rest in the ECG =500 msec or history of know long QT syndrome, Medical history of allergy to macrolides, Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation., Medical history of torsades de pointes arrhythmia, Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation., Concomitant presence of end-stage liver failure and end-stage renal failure., Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored., Any contradictions for macrolide uptake, Denial of written informed consent, Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study, Participation in any other interventional trial, Any stage IV malignancy, Any do not resuscitate decision, Patients necessitating non-invasive ventilation or mechanical ventilation, Hospitalization in Intensive Care Unit, Infection by SARS-CoV-2, Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days, Intake of any macrolide for the current episode of CAP under study
研究者
相似试验
进行中（未招募）
1 期
Biomarkers and treatment of pneumonia.EUCTR2015-002501-11-DKordsjællands Hospital300
已完成
不适用
Early clinical and biomarker responses after treatment in patients with non-segmental vitiligoVitiligo10035023NL-OMON48618Academisch Medisch Centrum36
招募中
3 期
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)Community-acquired PneumoniaNCT06294600Hellenic Institute for the Study of Sepsis330
已完成
不适用
Early Detection and Pharmacological Intervention for exercise-induced or cold-pressor-induced PHexercise-induced pulmonary hypertension, cold-pressor-induced pulmonary hypertensionJPRN-UMIN000029928Mie University Graduate School of Medicine Department of Cardiology and Nephrology50
已完成
4 期
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentIdiopathic Pulmonary FibrosisNCT02788474Boehringer Ingelheim347